TISSIUM, a medtech company developing biomorphic programmable polymers for tissue reconstruction, has appointed Sara Toyloy as its fourth independent member of the Board of Directors.
Shutterstock
Welcome aboard - signalling new appointments
Ms. Toyloy has over 30 years of experience in the medical device industry. In 2020, she founded Fabrica Consulting, a medical device consulting firm providing global regulatory and clinical trial strategies, where she currently serves as president.
Prior to this, she was at Elixir Medical Corporation for nearly 12 years, where she held several executive positions including president of New Therapies and chief regulatory officer and executive vice president of regulatory, clinical and quality.
She also served as executive vice president of Biosensors International Group, and vice president of regulatory and clinical affairs at Medtronic Vascular.
Ms. Toyloy began her career at Guidant Corporation (acquired by Boston Scientific in 2006) where she held several key roles, ultimately serving as Guidant's director of regulatory affairs and clinical research.
She also serves as a member of the board of directors of Shockwave Medical and she is a member of the California Community College Honor Scholarship Society.
Ms. Toyloy earned a B.S. Degree in Biological Sciences from California State University Hayward. The arrival of Ms. Toyloy to TISSIUM’s Board of Directors comes at a time of growth as TISSIUM continues to expand its platform and reach major regulatory milestones. Ms. Toyloy will be the second woman to be appointed to TISSIUM’s Board of Directors.
Christophe Bancel, CEO of TISSIUM, said: “We are excited to have a new member with such considerable experience in medtech joining the board at TISSIUM at such a key moment for the company. Sara’s experience and deep knowledge of healthcare regulations will be an invaluable asset as we advance the company toward commercialisation.”
Ms. Toyloy added: “I am honoured to join the TISSIUM Board of Directors. I look forward to helping TISSIUM continue the important work of transforming the lives of patients in need of better tissue reconstruction across multiple clinical indications and revolutionise the medtech industry.”
